JP2005514343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514343A5 JP2005514343A5 JP2003539701A JP2003539701A JP2005514343A5 JP 2005514343 A5 JP2005514343 A5 JP 2005514343A5 JP 2003539701 A JP2003539701 A JP 2003539701A JP 2003539701 A JP2003539701 A JP 2003539701A JP 2005514343 A5 JP2005514343 A5 JP 2005514343A5
- Authority
- JP
- Japan
- Prior art keywords
- drug composition
- composition according
- action
- oil
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 29
- 239000010648 geranium oil Substances 0.000 claims description 13
- 235000019717 geranium oil Nutrition 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 12
- 235000019198 oils Nutrition 0.000 claims description 12
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 4
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 3
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 3
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 3
- 229940099347 glycocholic acid Drugs 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims 4
- 208000007101 Muscle Cramp Diseases 0.000 claims 3
- 208000005392 Spasm Diseases 0.000 claims 3
- 230000002040 relaxant effect Effects 0.000 claims 3
- 230000008602 contraction Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 241000700198 Cavia Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 239000004575 stone Substances 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000927 lithogenic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011340908A CN1179735C (zh) | 2001-10-29 | 2001-10-29 | 一种治疗肝胆结石的溶石性药物及制备方法 |
| PCT/CN2002/000622 WO2003037358A1 (en) | 2001-10-29 | 2002-09-05 | A pharmaceutical composition having cholagogic and litholytic effect and its preparation method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005514343A JP2005514343A (ja) | 2005-05-19 |
| JP2005514343A5 true JP2005514343A5 (enExample) | 2008-10-23 |
| JP4593918B2 JP4593918B2 (ja) | 2010-12-08 |
Family
ID=4672224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003539701A Expired - Lifetime JP4593918B2 (ja) | 2001-10-29 | 2002-09-05 | 胆汁分泌促進、結石溶解作用を有する一種の薬物組成物、及びその製造方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20050042308A1 (enExample) |
| JP (1) | JP4593918B2 (enExample) |
| CN (1) | CN1179735C (enExample) |
| WO (1) | WO2003037358A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210742B (zh) * | 2010-04-09 | 2013-06-05 | 四川济生堂药业有限公司 | 薄荷素油在制备治疗胆汁淤积性肝病的药物中的应用 |
| CN112516213B (zh) * | 2020-12-30 | 2022-06-17 | 广西中医药大学 | 一种治疗胆结石的瑶药组合物、汤剂、胶囊剂及其应用 |
| CN113421620B (zh) * | 2021-05-17 | 2025-04-29 | 陕西中医药大学 | 基于uplc-q-tof/mse和整合效应的bp神经网络关联分析对中药不同功效的生物活性成分进行模糊识别的方法 |
| CN113624707B (zh) * | 2021-09-17 | 2024-06-18 | 云南博瑞生物科技有限公司 | 一种萝卜红气味定量检测方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60172925A (ja) * | 1984-02-17 | 1985-09-06 | Kao Corp | 胆石溶解剤 |
| JPH0757734B2 (ja) * | 1990-10-09 | 1995-06-21 | 呉羽化学工業株式会社 | 鎮静用香料組成物および香粧品 |
| CN1060964A (zh) * | 1990-10-29 | 1992-05-13 | 洛洪程 | 一种热伤药物的制取方法 |
| DE4330664A1 (de) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Verwendungen von Pflanzenölen |
| JPH07242536A (ja) * | 1994-03-01 | 1995-09-19 | Toyo Capsule Kk | 皮膜に精油成分が含有されたゼラチンカプセル剤 |
| JP3828163B2 (ja) * | 1994-06-10 | 2006-10-04 | サンスター株式会社 | 抗炎症、抗かゆみ剤 |
| EP0842604A1 (en) * | 1996-11-13 | 1998-05-20 | The Procter & Gamble Company | Sprayable disinfecting compositions and processes for disinfecting surfaces therewith |
| IL129102A0 (en) * | 1999-03-22 | 2000-02-17 | J P M E D Ltd | An emulsion |
| EP1146112A1 (en) * | 2000-04-14 | 2001-10-17 | The Procter & Gamble Company | Process of cleaning and/or disinfecting a hard surface with a composition comprising a biguanide antimicrobial agent |
-
2001
- 2001-10-29 CN CNB011340908A patent/CN1179735C/zh not_active Expired - Lifetime
-
2002
- 2002-09-05 WO PCT/CN2002/000622 patent/WO2003037358A1/zh not_active Ceased
- 2002-09-05 JP JP2003539701A patent/JP4593918B2/ja not_active Expired - Lifetime
- 2002-09-05 US US10/494,143 patent/US20050042308A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102088988B (zh) | 用于治疗或预防糖尿病和其它代谢失衡的方法 | |
| Everett et al. | The pharmacology of medieval sedatives: The “Great Rest” of the Antidotarium nicolai | |
| JP2021185145A (ja) | マカ組成物および使用方法 | |
| US9655870B2 (en) | Homeopathic drug composition and methods of use thereof | |
| AU2007334742B2 (en) | Tablet formulation | |
| CN113398110A (zh) | 一种脱落酸在制备治疗和/或改善多囊卵巢综合征的产品及用途 | |
| RU2601894C1 (ru) | Средство хронобиологической коррекции | |
| CN111265599A (zh) | 番茄红素和葡萄籽组合物在制备治疗关节炎药物中的应用 | |
| CN114832006B (zh) | 人参皂苷Rh4在制备用于抑制睡眠的药物中的用途 | |
| CN112587528B (zh) | 一种药物组合物及用于制备改善胰岛素抵抗、降血糖的药物的用途 | |
| CN106727480B (zh) | Fex-3在制备抗肥胖症药物中的应用 | |
| JP4593918B2 (ja) | 胆汁分泌促進、結石溶解作用を有する一種の薬物組成物、及びその製造方法 | |
| CN108186631A (zh) | 一种药物组合物及其制备方法和用途 | |
| Garg et al. | Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation | |
| CN115252607B (zh) | 一种组合物及在制备改善胰岛素抵抗、降血糖的药物中的应用 | |
| CN117695324B (zh) | 杜仲雄花花粉和/或杜仲雄花的新用途以及包含其的组合物 | |
| CN104784168B (zh) | 银杏内酯制备避孕药物中的用途 | |
| US8524759B2 (en) | Phenylbutazone carrier formulation showing increased bioactivity in animals | |
| RU2804224C1 (ru) | Способ профилактики диареи у новорожденных телят | |
| JP2007230954A (ja) | 睡眠誘導剤及びストレス性不眠症改善剤 | |
| CN115702933B (zh) | 一种用于辅助降低血糖的组合物 | |
| JP2003321383A (ja) | 更年期障害治療用組成物、性ホルモン上昇用組成物 | |
| Hameed et al. | Impact of Natural Plant on characterization of Nano Biomaterial for Blood Toxicology | |
| CN117717555A (zh) | 一种可溶性常山酮抗球虫组合物 | |
| Mohammad et al. | The investigation into the effect of flouxetine on quantity of ovarian follicles in adult female rats |